Recent insights into humoral and cellular immune responses against malaria

Trends in Parasitology

Volumn 24, Issue 12, 2008, Pages 578-584

  Beeson, James G ^a   Osier, Faith H A ^b   Engwerda, Christian R ^c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CD8ALPHA ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 6; MEMBRANE ANTIGEN; PARASITE ANTIGEN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CELLULAR IMMUNITY; DENDRITIC CELL; ERYTHROCYTE; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MALARIA; MEROZOITE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM YOELII; REGULATORY T LYMPHOCYTE; REVIEW; SPOROZOITE;

ANTIBODY FORMATION; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; MALARIA;

ANIMALIA;

EID: 55549094399     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.08.008     Document Type: Review

References (75)

1. Mackintosh C.L., et al. Clinical features and pathogenesis of severe malaria. Trends Parasitol. 20 (2004) 597-603
2. Marsh K., and Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 28 (2006) 51-60
3. Pombo D.J., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360 (2002) 610-617
4. Cohen S., et al. Gamma-globulin and acquired immunity to human malaria. Nature 192 (1961) 733-737
5. Sabchareon A., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45 (1991) 297-308
6. Rotman H.L., et al. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J. Immunol. 161 (1998) 1908-1912
7. Bull P.C., and Marsh K. The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol. 10 (2002) 55-58
8. Good M.F., et al. The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol. Rev. 201 (2004) 254-267
9. Achtman A.H., et al. Longevity of the immune response tand memory to blood-stage malaria infection. Curr. Top. Microbiol. Immunol. 297 (2005) 71-102
10. Osier F.H., et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76 (2008) 2240-2248
11. Cohen S., et al. Action of malarial antibody in vitro. Nature 223 (1969) 368-371
12. Bouharoun-Tayoun H., et al. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172 (1990) 1633-1641
13. Marsh K., et al. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83 (1989) 293-303
14. Perraut R., et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J. Infect. Dis. 191 (2005) 264-271
15. Roussilhon C., et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 4 (2007) e320
16. Malkin E.M., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73 (2005) 3677-3685
17. Duraisingh M.T., et al. Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes. EMBO J. 22 (2003) 1047-1057
18. Stubbs J., et al. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science 309 (2005) 1384-1387
19. Persson K.E.M., et al. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J. Clin. Invest. 118 (2008) 342-351
20. Hodder A.N., et al. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69 (2001) 3286-3294
21. Egan A.F., et al. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21 (1999) 133-139
22. O'Donnell R.A., et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193 (2001) 1403-1412
23. Adams J.H., et al. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7085-7089
24. Grimberg B.T., et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 4 (2007) e337
25. King C.L., et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8363-8368
26. Nogueira P.A., et al. A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N Terminus but not the C Terminus of merozoite surface protein 1. Infect. Immun. 74 (2006) 2726-2733
27. Michon P., et al. The risk of malarial infections and disease in Papua New Guinean children. Am. J. Trop. Med. Hyg. 76 (2007) 997-1008
28. Beeson J.G., and Brown G.V. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cell. Mol. Life Sci. 59 (2002) 258-271
29. Leech J.H., et al. Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes. J. Exp. Med. 159 (1984) 1567-1575
30. Biggs B.A., et al. Antigenic variation in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 9171-9174
31. Smith J.D., et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82 (1995) 101-110
32. Marsh K., and Howard R.J. Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science 231 (1986) 150-153
33. Bull P.C., et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 4 (1998) 358-360
34. Bull P.C., et al. Plasmodium falciparum variant surface antigen expression patterns during malaria. PLoS Pathog. 1 (2005) e26
35. Kaestli M., et al. Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. J. Infect. Dis. 193 (2006) 1567-1574
36. Jensen A.T., et al. Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J. Exp. Med. 199 (2004) 1179-1190
37. Salanti A., et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J. Exp. Med. 200 (2004) 1197-1203
38. Trimnell A.R., et al. Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Mol. Biochem. Parasitol. 148 (2006) 169-180
39. Beeson J.G., et al. Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies. J. Infect. Dis. 193 (2006) 721-730
40. Dahlback M., et al. Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog. 2 (2006) e124
41. Andersen P., et al. Structural Insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS Pathog. 4 (2008) e42
42. Avril M., et al. Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA. Infect. Immun. 76 (2008) 1791-1800
43. Keen J., et al. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med. 4 (2007) e181
44. Good M.F., et al. Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu. Rev. Immunol. 23 (2005) 69-99
45. Carvalho L.H., et al. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat. Med. 8 (2002) 166-170
46. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 (2003) 337-339
47. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 (2003) 339-342
48. Clark I.A., et al. Understanding the role of inflammatory cytokines in malaria and related diseases. Travel Med. Infect. Dis. 6 (2008) 67-81
49. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
50. Coban C., et al. Manipulation of host innate immune responses by the malaria parasite. Trends Microbiol. 15 (2007) 271-278
51. Togbe D., et al. Murine cerebral malaria development is independent of toll-like receptor signaling. Am. J. Pathol. 170 (2007) 1640-1648
52. Couper K.N., et al. Macrophage-mediated but gamma interferon-independent innate immune responses control the primary wave of Plasmodium yoelii parasitemia. Infect. Immun. 75 (2007) 5806-5818
53. Engwerda C.R., and Good M.F. Interactions between malaria parasites and the host immune system. Curr. Opin. Immunol. 17 (2005) 381-387
54. deWalick S., et al. Cutting edge: conventional dendritic cells are the critical APC required for the induction of experimental cerebral malaria. J. Immunol. 178 (2007) 6033-6037
55. Lundie, R.J. et al. Blood-stage Plasmodium infection induces CD8+ cytotoxic T lymphocyte effectors specific for parasite-expressed antigens, largely regulated by CD8 alpha+ dendritic cells. Proc. Natl. Acad. Sci. U. S. A. (in press)
56. Wykes M.N., et al. Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog. 3 (2007) e96
57. Wykes M.N., et al. Systemic tumor necrosis factor generated during lethal Plasmodium infections impairs dendritic cell function. J. Immunol. 179 (2007) 3982-3987
58. Engwerda C., et al. Experimental models of cerebral malaria. Curr. Top. Microbiol. Immunol. 297 (2005) 103-143
59. Grau G.E., et al. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237 (1987) 1210-1212
60. Lucas R., et al. Respective role of TNF receptors in the development of experimental cerebral malaria. J. Neuroimmunol. 72 (1997) 143-148
61. Engwerda C.R., et al. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J. Exp. Med. 195 (2002) 1371-1377
62. Togbe D., et al. Both functional LTbeta receptor and TNF receptor 2 are required for the development of experimental cerebral malaria. PLoS One 3 (2008) e2608
63. Hansen D.S., et al. NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J. Immunol. 178 (2007) 5779-5788
64. Miu J., et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J. Immunol. 180 (2008) 1217-1230
65. Campanella G.S., et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4814-4819
66. Van den Steen P.E., et al. CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur. J. Immunol. 38 (2008) 1082-1095
67. Stephens R., et al. Malaria-specific transgenic CD4(+) T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody production for parasite clearance. Blood 106 (2005) 1676-1684
68. Chakravarty S., et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 13 (2007) 1035-1041
69. Amino R., et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat. Med. 12 (2006) 220-224
70. Amante F.H., et al. A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am. J. Pathol. 171 (2007) 548-559
71. Vigario A.M., et al. Regulatory CD4+ CD25+ Foxp3+ T cells expand during experimental Plasmodium infection but do not prevent cerebral malaria. Int. J. Parasitol. 37 (2007) 963-973
72. Nie C.Q., et al. CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect. Immun. 75 (2007) 2275-2282
73. Couper K.N., et al. Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J. Immunol. 178 (2007) 4136-4146
74. Walther M., et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 23 (2005) 287-296
75. Liu Y., et al. A critical function for TGF-beta signaling in the development of natural CD4(+)CD25(+)Foxp3(+) regulatory T cells. Nat. Immunol. 9 (2008) 632-640